会议召开地点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 证券代码：688166 证券简称：博瑞医药 公告编号：2023-059 博瑞生物医药（苏州）股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 8 月 28 日（星期一）上午 10:00-11:00 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 21 日（星期一）至 8 月 25 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@bright-gene.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）将于 2023 年 8 月 25 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况， ...

证券代码：688166 证券简称：博瑞医药 公告编号：2023-037 博瑞生物医药（苏州）股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 15 日(星期一) 下午 13:00-14:30 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 本次投资者说明会以视频录播结合网络文字互动方式召开，公司将针对 2022 年度经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 15 日下午 13:00-14:30 （二）会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心视频 ...

Corporate Social Responsibility - The company donated a total of 350,400 CNY in cash during the reporting period[4] - The company has implemented a collective contract to protect employee rights and ensure fair compensation practices[5] - The company has received multiple honors for its intellectual property management, including recognition as a national intellectual property advantage enterprise[17] Investor Relations - The company held three earnings briefings during the reporting period to enhance investor communication[13] - The company has set up a dedicated investor relations section on its website to facilitate communication with investors[15] - A total of 105 announcements were disclosed by the company in 2022, ensuring transparency in information disclosure[16] Quality Management - The company has established a supplier management system to ensure quality control and compliance with regulations[9] - The company has established a comprehensive quality management system to monitor and enhance product safety[10] - No product recalls occurred in 2022 due to safety and health reasons, indicating effective product safety management[10] Shareholder Commitments - The company has committed to a share lock-up period of 36 months starting from November 8, 2019, for major shareholders including Yuan Jiandong and Zhong Weifang[1] - The company has received commitments from various investment partnerships to not transfer or manage their shares during the lock-up period, ensuring stability in shareholding[2] - The company has outlined a long-term commitment from major shareholders regarding their shareholding intentions, which is detailed in the IPO prospectus[3] - The company has established measures to avoid any potential competition with its major shareholders, ensuring alignment of interests[4] - The company has committed to repurchase shares if it is found to have engaged in fraudulent issuance during the IPO process[5] - The company has a commitment to maintain the integrity of its operations and avoid conflicts of interest with its major shareholders[6] - The company has outlined specific penalties for shareholders who violate their commitments, ensuring accountability[7] - The company has received commitments from shareholders to not engage in similar business activities that could compete with the company[8] - The company has established a framework for resolving any potential conflicts of interest that may arise in the future[9] - The company has ensured that all commitments made by shareholders are binding and cannot be revoked during their control period[10] - The company has committed to avoiding any business competition with its controlling shareholders, ensuring no similar business activities will be conducted by them or their controlled entities[34] Financial Performance - The company's operating revenue for 2022 was CNY 1,017,331,488.33, a decrease of 3.33% compared to CNY 1,052,408,590.87 in 2021[114] - The net profit attributable to shareholders for 2022 was CNY 239,623,172.71, down 1.77% from CNY 243,951,048.34 in the previous year[114] - The net cash flow from operating activities increased by 76.78% to CNY 311,259,089.32 in 2022, compared to CNY 176,075,346.56 in 2021[114] - The company's total assets grew by 56.97% to CNY 4,661,272,248.84 at the end of 2022, up from CNY 2,969,615,063.74 at the end of 2021[114] - The net assets attributable to shareholders increased by 30.60% to CNY 2,191,643,269.63 at the end of 2022, compared to CNY 1,678,188,732.58 at the end of 2021[114] - Research and development expenses accounted for 20.35% of operating revenue in 2022, an increase of 3.88 percentage points from 16.47% in 2021[116] - The basic earnings per share for 2022 was CNY 0.58, a decrease of 3.33% from CNY 0.60 in 2021[116] - The company reported a total of CNY 25,984,845.17 in non-recurring gains and losses for 2022, compared to CNY 19,633,858.57 in 2021[119] Market Trends - The global biopharmaceutical market is expected to reach $1.711 trillion by 2025, with a CAGR of 5.3% from 2021 to 2025[71] - The Chinese generic drug market was approximately ¥906.9 billion in 2021, showing a year-on-year growth of 7.39%[74] - The oncology treatment market is projected to grow from $193 billion in 2022 to $377 billion by 2027, with a CAGR of 14.3%[75] Research and Development - The company is focusing on developing high-quality generic drugs and innovative drugs to meet unmet clinical needs, particularly in oncology and chronic diseases[81] - The company has established multiple drug technology research platforms, including fermentation semi-synthesis, multi-chirality drug, non-biological macromolecule, drug-device combination, and conjugated drug platforms, covering various therapeutic areas such as antifungal, antiviral, immunosuppressive, and oncology[85] - The company is enhancing its R&D capabilities to align with the industry's shift towards quality and innovation, aiming to capture a larger share of the international market[74] - The company is actively pursuing regulatory approvals in multiple international markets to enhance its global presence[108] - The company is committed to developing antibody-drug conjugates (ADC) as a key area in its oncology research, with several ADC drugs recently approved by the FDA[171] Product Development - The company has developed complex multi-chiral drugs, including Posaconazole with four chiral centers and 21 synthesis steps, and the anticancer drug Elagolix with 19 chiral centers and 69 synthesis steps[109] - The company has received drug registration approval for the injectable formulation of Curbetadine, which is currently in the small trial phase[192] - The company has received drug registration approval for the inhalation solution of Budesonide, which is in the pilot test phase and targets asthma treatment[197] - The company is developing inhalation products, with several formulations in the pilot stage and clinical approval for Atropine Eye Drops already obtained[169] Financial Commitments and Guarantees - The company provided guarantees totaling 50,000,000 RMB, which represents 22.81% of the company's net assets[59] - The company has reported a total of 17,000,000 RMB in related party transactions for 2022, with actual amounts totaling 4,773,900 RMB, indicating a significant variance[54] - The company has completed construction and equipment debugging for the Suzhou high-end injectable drug production project, which complies with cGMP standards[144] Strategic Initiatives - The company is actively investing in innovative biotech firms, including BRIGHT INNOVATIVE LP, focusing on early-stage biomedicine and health technology[148] - The company is focusing on expanding its global market presence and enhancing international operational capabilities as part of its strategic initiatives[126] - The company is expanding its market presence through direct customer development and partnerships with local agents, leveraging its strong reputation for product quality[94]

Financial Performance - The company reported a revenue of CNY 304,937,396.25 for Q1 2023, representing a year-on-year increase of 22.77%[4] - Net profit attributable to shareholders was CNY 70,769,470.45, reflecting a growth of 16.48% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 69,711,194.90, up by 15.58% year-on-year[4] - Basic and diluted earnings per share were both CNY 0.17, an increase of 13.33% from the previous year[4] - In Q1 2023, the company achieved product sales revenue of CNY 267.94 million, a year-on-year increase of 19.90%[37] - The revenue from raw material products was CNY 221.18 million, up 6.50% year-on-year[37] - The revenue from formulation products reached CNY 46.75 million, a significant increase of 196.10% year-on-year, accounting for 17.45% of total product sales revenue, up 10.38 percentage points from the previous year[37] - Technology revenue amounted to CNY 24.64 million, reflecting a growth of 38.35% compared to the same period last year[37] - Equity income reached CNY 12.37 million, representing a substantial increase of 75.69% year-on-year[37] - Operating profit for Q1 2023 was RMB 75,605,620.79, an increase from RMB 65,287,387.64 in Q1 2022[45] Research and Development - Total R&D investment amounted to CNY 48,657,672.09, which is 15.96% of the revenue, a decrease of 1.25 percentage points compared to last year[4] - The company submitted 27 domestic patent applications and 6 international patent applications in Q1 2023, with a total of 397 patent applications filed to date[19] - The company reported a total of 205 valid patents, including 197 invention patents, as of March 31, 2023[19] - The company’s research and development center project is in the equipment installation and debugging phase, with significant advancements in the construction of the production base[21] Assets and Liabilities - The company's total assets at the end of Q1 2023 were CNY 4,777,033,986.25, a 2.48% increase from the end of the previous year[5] - In Q1 2023, the company achieved a total asset of approximately CNY 4.78 billion, an increase from CNY 4.66 billion in the previous quarter, reflecting a growth of about 2.5%[22] - The company’s total liabilities increased to approximately CNY 1.86 billion from CNY 1.83 billion, indicating a growth of about 1.6%[24] - The total liabilities decreased slightly to CNY 2,408.38 million from CNY 2,419.59 million year-on-year[26] - The total equity increased to CNY 2,368.65 million from CNY 2,241.69 million year-on-year[27] Cash Flow and Investments - The company's net cash flow from operating activities was CNY 25.06 million, compared to a negative cash flow of CNY 29.65 million in the same period last year[32] - The company reported a net increase in cash and cash equivalents of CNY -162.47 million, compared to CNY -8.75 million in the same period last year[35] - Cash and cash equivalents decreased to approximately CNY 1.02 billion from CNY 1.18 billion, representing a decline of about 13.7%[22] - The company’s long-term equity investments decreased slightly to approximately CNY 33.92 million from CNY 35.37 million, a decline of about 4.1%[24] - The company’s short-term borrowings increased to approximately CNY 164.35 million from CNY 124.38 million, reflecting a rise of about 32.2%[24] Infrastructure Development - The company completed 90% of the curtain wall construction for the workshop and 95% for the headquarters building, indicating significant progress in infrastructure development[21] - The company is preparing for trial production at several new facilities, including the Taixing raw material and formulation production base[10] Market Strategy - The company plans to continue expanding its market presence and investing in new product development[44] - The company is not applying new accounting standards for the year 2023[48]

Group 1: Company Development and Strategy - The company focuses on R&D-driven strategies, aiming to develop both high-barrier generic drugs and highly differentiated innovative drugs [2][4] - R&D investments will be aligned with operational cash flow to select suitable business models [2] - The company plans to maintain a balance in R&D investments while controlling them within reasonable limits [2] Group 2: Financial Performance - In Q1 2022, the gross profit margin increased due to significant growth in high-margin products, such as: - Anifin raw materials: Revenue increased by 127.39%, gross margin over 80% [3] - Micafungin raw materials: Revenue increased by 83.33%, gross margin over 70% [3] - Dapoxetine raw materials: Revenue increased by 406.53%, gross margin over 70% [3] - The company's products are entering commercialization, leading to economies of scale and effective cost control, significantly enhancing gross profit levels [3] Group 3: Market Expansion Plans - The company aims to enhance its global market presence, focusing primarily on the European and American markets while also exploring Southeast Asia, Belt and Road Initiative markets, the Middle East, South America, and North Africa [3] - The company has established production bases in Suzhou and Taixing, along with an internationally aligned quality management system [3] Group 4: Product Development Focus - The company emphasizes high-barrier inhalation products, such as dry powder inhalers and soft mist inhalers, which have significant clinical and commercial value [4] - In innovative drug development, the focus will be on: - Antibody-drug conjugates (ADCs) for targeted delivery in cancer treatment, with potential for improvement in penetration and efficacy [4] - Drug-device combinations that leverage a technological platform for sustainable innovation [4]

证券代码：688166 证券简称：博瑞医药 博瑞生物医药（苏州）股份有限公司 投资者关系活动记录表 编号：2022-006 | --- | --- | --- | |---------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| ...

Financial Performance - The company's revenue for Q3 2022 was ¥271,971,006.83, representing a year-over-year increase of 0.99%[5] - Net profit attributable to shareholders for Q3 2022 was ¥85,622,530.05, an increase of 22.31% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥86,260,922.43, up 24.09% year-over-year[5] - The basic earnings per share for Q3 2022 was ¥0.21, reflecting a 23.53% increase year-over-year[5] - For the first nine months of 2022, the company achieved operating revenue of RMB 772.32 million, a year-on-year increase of 3.19%[15] - The net profit attributable to shareholders for the same period was RMB 197.62 million, reflecting a year-on-year growth of 11.73%[15] - In Q3 2022, the company's operating revenue grew by 0.99% year-on-year, while the net profit attributable to shareholders increased by 22.31%[15] - Total operating revenue for the first three quarters of 2022 reached ¥772,321,355.75, an increase from ¥748,440,872.31 in the same period of 2021, representing a growth of approximately 3.7%[30] - Net profit for the third quarter of 2022 was ¥177,878,679.31, slightly up from ¥170,780,575.00 in the previous year, reflecting a growth of approximately 4.1%[34] Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥4,086,290,770.81, a 37.60% increase from the end of the previous year[7] - The company's total liabilities amounted to ¥2,073,869,767.97, a significant increase from ¥1,227,980,082.88 in the previous period, marking a rise of about 69%[28] - The total equity attributable to shareholders reached ¥2,012,421,002.84, up from ¥1,741,634,980.86, which is an increase of approximately 15.5%[29] - The total liabilities and equity amounted to ¥4,086,290,770.81, up from ¥2,969,615,063.74, reflecting an increase of about 37.8%[29] Research and Development - R&D investment totaled ¥45,204,654.13 in Q3 2022, accounting for 16.62% of revenue, an increase of 1.60 percentage points from the previous year[7] - The company submitted 8 domestic patent applications and 2 foreign patent applications in Q3 2022, with a total of 356 patent applications filed to date[18] - Research and development expenses for the first three quarters of 2022 were ¥139,053,362.88, compared to ¥119,784,659.32 in 2021, showing an increase of about 16.0%[30] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥205,840,314.51, a significant increase of 149.28%[9] - Operating cash inflow for the first three quarters of 2022 reached RMB 922,221,335.76, an increase of 35.5% compared to RMB 680,266,726.68 in the same period of 2021[40] - Net cash flow from operating activities was RMB 205,840,314.51, up from RMB 82,574,695.65 in the previous year, representing a significant increase of 149.5%[40] - Cash inflow from investment activities totaled RMB 549,372,292.79, compared to RMB 312,232,702.80 in the previous year, marking a rise of 75.9%[41] - Net cash flow from investment activities was -RMB 793,963,854.22, worsening from -RMB 659,665,113.77 year-on-year[41] - Cash inflow from financing activities amounted to RMB 1,379,052,375.62, significantly higher than RMB 718,183,266.13 in the same period last year, an increase of 92%[41] - Net cash flow from financing activities was RMB 883,781,300.36, compared to RMB 553,064,914.12 in the previous year, reflecting a growth of 59.8%[41] - The company reported a net increase in cash and cash equivalents of RMB 300,184,511.17, contrasting with a decrease of RMB 22,123,636.36 in the same period of 2021[41] - The ending balance of cash and cash equivalents stood at RMB 633,399,193.09, up from RMB 317,409,878.26 year-on-year, indicating a growth of 99.5%[41] Government Subsidies and Tax Refunds - The company reported a total of ¥5,233,779.87 in government subsidies recognized in Q3 2022[8] - The company received RMB 75,465,505.99 in tax refunds, which is a 132.5% increase from RMB 32,462,495.74 in the previous year[40] Production and Capacity Expansion - The company has completed construction and verification of its first-phase raw material and formulation production base in Taixing[19] - The company has received drug clinical trial approval for BGC1201 tablets and marketing application approval for a raw material drug[16] - The company is in the process of expanding its production capacity with multiple projects, including the Suzhou high-end formulation drug production project[19]

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2022, representing a 20% increase compared to the same period last year[19]. - The company's operating revenue for the first half of the year reached ¥500,350,348.92, representing a 4.43% increase compared to the same period last year[26]. - Net profit attributable to shareholders was ¥112,001,271.81, up 4.80% year-over-year[26]. - The gross profit margin improved to 60%, up from 55% in the previous year, reflecting better cost management and pricing strategies[19]. - Product sales revenue reached 451.13 million yuan, up 7.25% year-on-year, with a gross margin of 59.48%, an increase of 6.91 percentage points compared to the previous year[99]. - The net profit excluding non-recurring gains and losses decreased by 8.31% to 94.94 million yuan[99]. - The revenue from raw material drugs was 393.27 million yuan, a decrease of 0.87%, with a gross margin of 57.22%, up 4.90 percentage points year-on-year[100]. - The overseas revenue from equity sharing decreased by 38.63% to 22.18 million yuan due to the maturity of corresponding products and sales progress limitations[101]. Research and Development - Research and development expenses increased by 30% to 150 million CNY, focusing on innovative drug development and technology enhancements[19]. - The company's R&D expenditure accounted for 18.76% of operating revenue, an increase of 2.2 percentage points compared to the previous year[26]. - Research and development (R&D) expenses amounted to ¥93,848,708.75, representing an 18.29% increase compared to ¥79,336,152.47 in the same period last year[67]. - The company is focusing on developing ADC drug technology services and has made significant progress in clinical trials for innovative drugs like BGC0228 and BGC1201[103]. - The company has submitted several products for regulatory approval during the reporting period, marking significant milestones in its R&D efforts[65]. - The company has developed a comprehensive product line covering antiviral, antifungal, immunosuppressive, respiratory, and oncology treatments, with key products including Entecavir and Oseltamivir[32]. - The company is developing peptide-drug conjugates that offer advantages such as enhanced tumor penetration and lower production costs compared to larger antibody-drug conjugates[60]. - The company is currently in Phase I clinical trials for the injectable BGC0228 project, with a total investment of ¥5,000,000 and cumulative investment of ¥3,162,710[70]. Market Expansion and Strategy - The company expects a revenue growth forecast of 25% for the second half of 2022, driven by new product launches and market expansion strategies[19]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[19]. - The company aims to break reliance on a single market by expanding globally, with strategies including building cGMP-compliant production systems and attracting international talent[44][46]. - The company is pursuing global market expansion and has invested in innovative technology companies to enhance its future drug pipeline[37]. - The company is actively participating in national bulk purchasing programs to enhance hospital coverage for its products, with its injectable Micafungin sodium expected to be selected in the seventh batch of national drug procurement[33]. Financial Position and Assets - Total assets grew by 32.73% to ¥3,941,462,212.63, mainly due to the arrival of funds from convertible bonds[26]. - The company's cash and cash equivalents at the end of the period amounted to ¥590,028,379.62, representing 14.97% of total assets, an increase of 75.17% compared to the previous year[138]. - Accounts receivable reached ¥435,041,340.96, accounting for 11.04% of total assets, with a year-on-year increase of 16.52%[138]. - Inventory stood at ¥236,982,858.33, making up 6.01% of total assets, reflecting an 18.46% increase from the previous year[138]. - Long-term equity investments decreased by 21.81% to ¥40,886,473.82, representing 1.04% of total assets[138]. Risks and Challenges - The company has identified potential risks related to regulatory changes and market competition, which are detailed in the risk factors section[19]. - The company faces risks related to the volatility of performance due to reliance on customer R&D progress, which can lead to fluctuations in revenue[121]. - The company faces risks related to tax policy changes, currency fluctuations, and industry competition that could impact future performance[126][129]. - The company has established a strict quality management system to ensure compliance with national standards, but faces risks related to production quality control and potential safety incidents[123]. Environmental and Compliance - The company has implemented various pollution control facilities, including activated carbon adsorption for waste gas treatment[169]. - The environmental impact assessments for the production bases of raw materials and formulations in Taixing have been approved, with specific approval numbers provided[170]. - Borui Taixing holds pollution discharge permits valid until 2027, ensuring compliance with environmental regulations[173]. - The company has been conducting environmental monitoring every six months through a qualified third party, with total environmental investment increasing year by year in line with the rising trend of pollutant emissions[175]. - All subsidiaries have actively complied with national and local environmental regulations, with no violations or penalties reported by the end of the reporting period[177]. Corporate Governance and Shareholder Matters - The company has committed to various shareholder and management promises, including a 36-month lock-up period for certain shares starting from November 8, 2019[182]. - The company has not disclosed any other environmental information due to non-applicability during the reporting period[178]. - The company has not reported any changes or updates regarding previously disclosed environmental information during the reporting period[178]. - There are no significant lawsuits or arbitration matters reported during the reporting period[199]. - The company has not engaged in any non-operating fund occupation by major shareholders or related parties[197].

Financial Performance - The company's revenue for Q1 2022 was CNY 248,373,219.05, representing a year-on-year increase of 31.53%[5] - Net profit attributable to shareholders was CNY 60,754,391.10, reflecting a growth of 25.00% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was CNY 60,315,257.52, up 26.83% year-on-year[5] - The total operating revenue for Q1 2022 was ¥248,373,219.05, an increase from ¥188,839,905.34 in Q1 2021, representing a growth of approximately 31.6%[36] - The total profit for the current period is 65,299,553.52 RMB, an increase from 54,520,921.14 RMB in the previous period, representing a growth of approximately 19.5%[39] - The net profit attributable to shareholders of the parent company is 60,754,391.10 RMB, compared to 48,604,937.62 RMB in the previous period, reflecting an increase of about 25%[39] - Basic and diluted earnings per share for the current period are both 0.15 RMB, up from 0.12 RMB in the previous period, indicating a growth of 25%[41] Cash Flow - The net cash flow from operating activities was negative at CNY -29,648,247.48, a significant decline of 957.37% year-on-year[5] - The company's cash flow from operating activities was impacted by increased R&D and sales promotion expenses, leading to slower cash inflow growth[8] - Cash inflows from operating activities totaled 223,452,577.04 RMB, compared to 217,713,663.33 RMB in the previous period, showing an increase of approximately 2.5%[43] - Cash outflows from operating activities amounted to 253,100,824.52 RMB, compared to 214,255,625.31 RMB in the previous period, representing an increase of about 18.1%[43] - The net cash flow from operating activities is -29,648,247.48 RMB, a decline from 3,458,038.02 RMB in the previous period[47] - Cash inflows from investing activities were 70,266,275.88 RMB, down from 181,262,465.76 RMB in the previous period, indicating a decrease of approximately 61.2%[47] - Cash outflows from investing activities totaled 713,590,475.27 RMB, compared to 407,196,914.90 RMB in the previous period, reflecting an increase of about 75.1%[47] - The net cash flow from financing activities is 664,453,061.70 RMB, compared to 255,955,908.71 RMB in the previous period, showing an increase of approximately 159.7%[47] - The ending balance of cash and cash equivalents is 324,463,902.63 RMB, down from 377,669,961.10 RMB in the previous period[47] Research and Development - Total R&D expenses amounted to CNY 42,737,799.16, which is an increase of 93.19% year-on-year, accounting for 17.21% of total revenue[5][12] - R&D expenses amounted to RMB 42.74 million, a 93.19% increase year-on-year, representing 17.21% of operating revenue[22] - The company submitted 6 domestic patent applications and 2 foreign patent applications during Q1 2022, with a total of 334 patent applications filed to date[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,630,151,545.43, up 22.24% from the previous year[7] - The total assets as of the end of the reporting period were ¥3,630,151,545.43, compared to ¥2,969,615,063.74 at the same time last year, showing a growth of approximately 22.3%[33] - The total liabilities increased to ¥1,749,943,725.24 in Q1 2022 from ¥1,227,980,082.88 in Q1 2021, representing a rise of about 42.5%[33] - The equity attributable to shareholders of the parent company reached ¥1,816,715,512.63, up from ¥1,678,188,732.58 in the previous year, reflecting an increase of approximately 8.3%[33] - Long-term borrowings rose to ¥861,565,706.53 in Q1 2022 from ¥618,693,003.90 in Q1 2021, indicating an increase of about 39.2%[33] Sales Performance - The company's product sales revenue increased by 33.70% year-on-year, while technology revenue surged by 645.14%[8] - Product sales revenue reached RMB 223.47 million, a 33.70% increase compared to the same period last year; technology revenue surged to RMB 17.81 million, a remarkable growth of 645.14%[21] - The revenue from raw material drugs was RMB 207.81 million, with significant growth in specific products: Anifin raw material drug revenue increased by 127.39% and Micafungin raw material drug revenue rose by 83.33%[21] Construction Projects - The construction progress of the Taixing raw material drug and formulation production base is nearing completion, with major structural work finished[23] - The company’s Indonesian project has achieved a construction completion rate of 99.5%, with internal decoration at 98% completion[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 11,373[13] - The weighted average return on net assets was 3.45%, an increase of 0.11 percentage points compared to the previous year[5]

Financial Performance - The company's operating revenue for 2021 was CNY 1,052,408,590.87, representing a 34.00% increase compared to 2020[24]. - The net profit attributable to shareholders for 2021 was CNY 243,951,048.34, reflecting a 43.60% growth year-over-year[24]. - The net cash flow from operating activities for 2021 was CNY 176,075,346.56, an increase of 13.28% from the previous year[24]. - The basic earnings per share for 2021 was CNY 0.60, up 46.34% from CNY 0.41 in 2020[24]. - The company's gross profit margin was 56.23% during the reporting period[152]. - The company achieved a total revenue of 69,980 million RMB, with a net profit of 33,662.05 million RMB, indicating a strong financial performance[125]. R&D and Innovation - The company invested CNY 173.29 million in R&D, a 23.04% increase year-on-year, representing 16.47% of operating revenue[41]. - The company has submitted 15 new domestic patent applications and received 29 new domestic patent authorizations, totaling 326 patent applications, with 324 being invention patents[46]. - The company has developed multiple advanced drug technology platforms, including fermentation semi-synthesis, multi-chiral drugs, non-biological macromolecules, inhalation formulations, and conjugated drugs, covering various therapeutic areas[87][88][89][92][93][97]. - The innovative drug BGC0228 has received IND approval and is currently in Phase 1 clinical trials[41]. - The company reported a total R&D investment of approximately ¥173.29 million, representing a 23.04% increase from the previous year[108]. Market and Sales - The company’s main business revenue from product sales was CNY 927,795,300, which is a 38.38% increase year-on-year[165]. - The company’s foreign sales accounted for a significant portion of revenue, with foreign sales revenue reaching CNY 488,723,891.19, a 70.01% increase[169]. - The company is actively pursuing market expansion strategies, including partnerships for technology support and profit-sharing models with international pharmaceutical companies[133]. - The company has established a strong position in the pharmaceutical supply chain, allowing it to enjoy profit-sharing from clients' sales of formulation products[73]. Corporate Governance and Compliance - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report, assuming legal responsibility for any misstatements or omissions[4]. - The company has received a standard unqualified audit report from the accounting firm Tianye[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not disclosed any special arrangements for corporate governance[9]. Risks and Challenges - The company has detailed various risks faced during its operations in the report, emphasizing the importance of risk awareness for investors[5]. - The company faces potential risks from policy changes in the pharmaceutical industry, particularly regarding volume-based procurement and consistency evaluations[158]. - The company is exposed to risks from potential changes in tax policies that could increase income tax expenses[147]. - The company must maintain a stable and skilled technical talent team to sustain its competitive edge in the industry[140]. Production and Capacity - The company’s production capacity utilization rate remained high in 2021, with ongoing optimization of processes to reduce production costs[47]. - The company’s Taixing raw material and formulation production base has a planned capacity of 3,450 kg, with construction progressing to equipment validation stage[49]. - The company has invested a total of RMB 46.5 million in the Suzhou inhalation and other chemical drug formulation base project, with an annual design capacity of 64 million units[51]. Strategic Investments - The company has made equity investments in several innovative biotech firms, including RMB 20 million in Beijing InnoRuiKang and RMB 20 million in Suzhou Laitacon[55]. - The company invested $3.3 million in the Boryeong Indonesia project, which has a planned raw material capacity of approximately 3,677 kg, with 99% of civil engineering completed[54]. Product Development - The company has obtained production approval for Olanzapine injection and has passed the consistency evaluation for Micafungin sodium injection in China[45]. - The company’s innovative drug BGC0228 has received IND approval and is currently in Phase 1 clinical trials, while other drugs are in preclinical research stages[60]. - The company aims to complete clinical research for the new drug application of the Colchicine patch in the short term[119].